ES2548299B2 - Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama - Google Patents
Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama Download PDFInfo
- Publication number
- ES2548299B2 ES2548299B2 ES201430349A ES201430349A ES2548299B2 ES 2548299 B2 ES2548299 B2 ES 2548299B2 ES 201430349 A ES201430349 A ES 201430349A ES 201430349 A ES201430349 A ES 201430349A ES 2548299 B2 ES2548299 B2 ES 2548299B2
- Authority
- ES
- Spain
- Prior art keywords
- risk
- mir
- seq
- present
- recurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se sitúa en el campo de la oncología y el tratamiento del cáncer. La presente invención incluye métodos para pronosticar el riesgo de recurrencia de tumores de mama empleando la firma de expresión de determinados miARNs. Específicamente, la presente invención se refiere a un procedimiento para determinar el riesgo de recurrencia de cáncer de mama que comprende medir los niveles de expresión de al menos un miARN seleccionado de entre el grupo que consiste en miR-149-5p (SEQ ID NO: 1), miR-10a-5p, (SEQ ID NO: 2), miR-20b-5p, (SEQ ID NO: 3), miR-30a-3p (SEQ ID NO: 4); y miR-342-5p, (SEQ ID NO: 5) en una muestra del tumor, en el que una alteración del nivel de expresión de al menos un miARN en el tumor, con respecto al nivel de expresión en una muestra control, es indicativa de un elevado riesgo de recurrencia del tumor. Además, la presente invención se refiere a herramientas y kits para llevar a cabo el procedimiento de la presente invención.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430349A ES2548299B2 (es) | 2014-03-13 | 2014-03-13 | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama |
EP15760852.2A EP3144395B1 (en) | 2014-03-13 | 2015-03-13 | Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer |
US15/125,714 US10059998B2 (en) | 2014-03-13 | 2015-03-13 | Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer |
PCT/ES2015/070179 WO2015136141A1 (es) | 2014-03-13 | 2015-03-13 | Firma de microarn como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430349A ES2548299B2 (es) | 2014-03-13 | 2014-03-13 | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2548299A1 ES2548299A1 (es) | 2015-10-15 |
ES2548299B2 true ES2548299B2 (es) | 2016-05-13 |
Family
ID=54070984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201430349A Expired - Fee Related ES2548299B2 (es) | 2014-03-13 | 2014-03-13 | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama |
Country Status (4)
Country | Link |
---|---|
US (1) | US10059998B2 (es) |
EP (1) | EP3144395B1 (es) |
ES (1) | ES2548299B2 (es) |
WO (1) | WO2015136141A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102601499B1 (ko) * | 2015-11-06 | 2023-11-13 | 연세대학교 산학협력단 | miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법 |
WO2019177550A1 (en) | 2018-03-10 | 2019-09-19 | Koc Universitesi | Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same |
AR128976A1 (es) | 2022-03-11 | 2024-07-03 | Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet | Diagnóstico y tratamiento de cáncer de mama |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE447040T1 (de) * | 2002-09-03 | 2009-11-15 | Quanta Biosciences Inc | Verbesserte zusammensetzungen und verfahren für die cdna-synthese |
CA2780222C (en) * | 2009-11-04 | 2021-11-16 | Diamir, Llc | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
US20130065778A1 (en) | 2010-01-26 | 2013-03-14 | Yale University | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy |
EP2545190A1 (en) * | 2010-03-11 | 2013-01-16 | National University of Ireland Galway | Detection and quantification of micrornas in the circulation and the use of circulating micrornas as biomarkers for cancer |
CA2800557A1 (en) * | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
WO2013057567A1 (en) | 2011-10-19 | 2013-04-25 | Council Of Scientific And Industrial Research (C.S.I.R.) | Biomarkers useful for detection of types, grades and stages of human breast cancer |
WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
EP2682477A1 (en) | 2012-07-06 | 2014-01-08 | National University of Ireland, Galway | miR-181a and miR652 as oncologic biomarker of breast cancer |
-
2014
- 2014-03-13 ES ES201430349A patent/ES2548299B2/es not_active Expired - Fee Related
-
2015
- 2015-03-13 WO PCT/ES2015/070179 patent/WO2015136141A1/es active Application Filing
- 2015-03-13 US US15/125,714 patent/US10059998B2/en active Active
- 2015-03-13 EP EP15760852.2A patent/EP3144395B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10059998B2 (en) | 2018-08-28 |
EP3144395A4 (en) | 2018-01-03 |
US20170002424A1 (en) | 2017-01-05 |
EP3144395A1 (en) | 2017-03-22 |
EP3144395B1 (en) | 2019-11-20 |
WO2015136141A1 (es) | 2015-09-17 |
ES2548299A1 (es) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201908277TA (en) | Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) | |
MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
MX2020008976A (es) | Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1. | |
MX2017003790A (es) | Detección de secuencias diana por percepción de nanoporos de sondas sintéticas. | |
MX2017010836A (es) | Panel biomarcador para la deteccion de cancer. | |
MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
EP3744859A3 (en) | Microrna biomarker for the diagnosis of gastric cancer | |
MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
CY1122233T1 (el) | Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο | |
MX357402B (es) | Metodo para predecir el pronostico de cancer de mama. | |
CL2017001972A1 (es) | Biomarcadores para cáncer pancreático | |
WO2013148147A8 (en) | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms | |
BR112017012142A2 (pt) | método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama | |
CL2021002387A1 (es) | Métodos para predecir el cáncer de próstata y usos de los mismos | |
MX2019007894A (es) | Composiciones y metodos para detectar el adn tumoral circulante. | |
EP3444362A3 (en) | Circulating mirnas as early detection marker and prognostic marker | |
ES2548299B2 (es) | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama | |
MX2018005867A (es) | Integracion de las caracteristicas tumorales con el indice de cancer de mama. | |
MX2016012278A (es) | Deteccion temprana de preeclampsia. | |
WO2015115923A3 (en) | A profile of microrna in the blood as a test for the detection of lung cancer | |
MX2018009112A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. | |
BR112016005413A2 (pt) | usos de pelo menos um mirna, kit, métodos de diagnóstico de câncer de mama e métodos para avaliação de risco de metástase | |
MX2015016721A (es) | Metodo de pronostico en cancer de mama. | |
WO2014110230A3 (en) | Methods for diagnosing cancer based on small nucleolar rna hbii-52 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2548299 Country of ref document: ES Kind code of ref document: B2 Effective date: 20160513 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20230726 |